Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 9/20 | 0.72 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14019342 | 0.81 | METAP1 (0.61) | METAP1THRATHRBACHESIGMAR1 | |
| SCHEMBL6271181 | 0.80 | METAP1 (0.71) | METAP1CDK8CDK5ACHECYP19A1 | |
| SCHEMBL6270614 | 0.80 | METAP1 (0.71) | METAP1CDK8CDK5ACHECYP19A1 | |
| SCHEMBL15617637 | 0.78 | METAP1 (0.66) | METAP1THRATHRBACHECYP19A1 | |
| SCHEMBL6272087 | 0.77 | METAP1 (0.64) | METAP1THRATHRBACHECYP19A1 | |
| SCHEMBL10269432 | 0.73 | METAP1 (0.59) | METAP1ACHESIGMAR1CYP19A1 | |
| SCHEMBL2484416 | 0.71 | ACHE (0.73) | METAP1ACHE | |
| SCHEMBL25818510 | 0.70 | METAP1 (0.41) | METAP1CDK8CDK5ACHE | |
| SCHEMBL20364987 | 0.70 | DRD3 (0.76) | METAP1ACHESIGMAR1 | |
| SCHEMBL5198123 | 0.70 | METAP1 (0.62) | METAP1THRBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277645-A1 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005097093-A1 | SLEEP INDUCING COMPOUNDS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277645-A1 | Sleep inducing compounds and methods relating thereto | CNR1, CNR2, MTNR1B | METAP1 4516/4885THRA 168/4885THRB 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.